Home › Companies › TEVA PHARMACEUTICAL INDUSTRIES LTD. › 2024-2025

TEVA PHARMACEUTICAL INDUSTRIES LTD. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and TEVA PHARMACEUTICAL INDUSTRIES LTD.’s Form 8-K, filed 2025-06-05 (Item 5.07 on EDGAR). Page generated 04 October 2026.

19Reported items
530Asset managers
3,762Fund votes
2025-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore TEVA PHARMACEUTICAL INDUSTRIES LTD. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by TEVA PHARMACEUTICAL INDUSTRIES LTD.

These tallies are TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

TEVA PHARMACEUTICAL INDUSTRIES LTD. — official shareholder meeting results, meeting held 2025-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Chen Lichtenstein	654,450,171	135,306,461	13,065,014	--	61,943,377	Majority: yes
Elect Director: Amir Elstein	628,249,902	172,959,185	1,606,559	--	61,943,377	Majority: yes
Elect Director: Roberto A. Mignone	652,577,603	137,177,350	13,060,693	--	61,943,377	Majority: yes
Elect Director: Dr. Perry D. Nisen	644,697,802	145,078,739	13,039,105	--	61,943,377	Majority: yes
Elect Director: Dr. Tal Zaks	653,460,760	136,254,343	13,100,531	--	61,943,377	Majority: yes
(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows:	688,836,027	99,207,637	14,771,995	--	61,943,377	Majority: yes
Elect Director: Did not indicate "YES" for personal interest	704,221,967	90,789,459	1,799,855	--	0	Majority: yes
(4) The shareholders approved an amendment to the terms of office and employment of Teva's President and Chief Executive Officer, as follows:	723,482,261	77,535,212	1,798,161	--	61,943,377	Majority: yes
(5A) The shareholders approved an amendment to the compensation to be provided to Teva's non-employee Directors, as follows:	773,824,912	27,111,172	1,878,351	--	61,943,377	Majority: yes
(5B) The shareholders approved an amendment to the compensation to be provided to Teva's non-executive Chairman of the Board, as follows:	772,020,910	29,129,637	1,665,087	--	61,943,377	Majority: yes
(6) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd.	820,210,234	35,027,740	3,504,417	--	0	Majority: yes

Source: TEVA PHARMACEUTICAL INDUSTRIES LTD., Form 8-K, filed with the SEC on 2025-06-05 — read the filing on EDGAR.

How asset managers voted at the TEVA PHARMACEUTICAL INDUSTRIES LTD. 2024-2025 meeting

Each item below shows how the 530 asset managers that disclosed a TEVA PHARMACEUTICAL INDUSTRIES LTD. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 22 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 688,836,027AGAINST: 99,207,637

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows:”): 688,836,027 for, 99,207,637 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 60% for, 9% against (69% of the company cast a for/against vote).

The 517 asset managers below cast 95% of the shares they voted on this item FOR (635,023,607 for, 35,423,551 against).

FOR 94%

FOR: 635,023,607 (94.4%)AGAINST: 35,423,551 (5.3%)ABSTAIN: 2,102,398 (0.3%)NOT VOTED: 37,918 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation for Teva's named executive officers” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
Fidelity	143,703,200	0	For
BlackRock	58,609,600	0	For
Vanguard	42,222,470	0	For
Clal Insurance Enterprises Holdings Ltd	37,189,951	0	For
MENORA MIVTACHIM HOLDINGS LTD.	29,470,227	0	For
Phoenix Financial Ltd.	27,933,834	0	For
Rubric Capital Management LP	19,665,521	0	For
Lingotto Investment Management LLP	18,297,095	0	For
State Street	16,960,818	389,082	For
Duquesne Family Office LLC	15,968,935	0	For
PointState Capital LP	14,959,809	0	For
GLENVIEW CAPITAL MANAGEMENT, LLC	13,305,016	0	For
VIKING GLOBAL INVESTORS LP	12,370,004	0	For
Allspring	10,680,748	0	For
Slate Path Capital LP	9,655,998	0	For
GEODE CAPITAL MANAGEMENT, LLC	9,200,754	0	For
SOUND SHORE MANAGEMENT INC /CT/	9,041,532	0	For
AustralianSuper Pty Ltd	0	8,627,451	Against
Invesco	7,678,787	0	For
Charles Schwab	7,169,470	0	For
Y.D. More Investments Ltd	0	7,096,532	Against
Victory Capital	6,669,496	0	For
Ion Asset Management Ltd.	5,943,028	0	For
Janus Henderson	5,854,011	0	For
Capital Group	5,347,963	0	For

Showing the 25 largest of 517 asset managers. See all 517 in the interactive database.

2. To approve the compensation to be provided to Teva's non- executive chairman of the board

COMPENSATIONMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 772,020,910AGAINST: 29,129,637

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“(5B) The shareholders approved an amendment to the compensation to be provided to Teva's non-executive Chairman of the Board, as follows:”): 772,020,910 for, 29,129,637 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 67% for, 3% against (70% of the company cast a for/against vote).

The 96 asset managers below cast 96% of the shares they voted on this item FOR (184,315,398 for, 7,457,294 against).

FOR 96%

FOR: 184,315,398 (96.1%)AGAINST: 7,457,294 (3.9%)ABSTAIN: 32,666 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “To approve the compensation to be provided to Teva's non- executive chairman of the board” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
Fidelity	61,691,893	0	For
Vanguard	28,917,292	0	For
BlackRock	22,325,535	0	For
Lingotto Investment Management LLP	18,297,095	0	For
SOUND SHORE MANAGEMENT INC /CT/	9,041,532	0	For
Y.D. More Investments Ltd	0	7,096,532	Against
Allspring	4,566,476	0	For
Charles Schwab	3,535,795	0	For
Victory Capital	3,259,354	0	For
JANUS INVESTMENT FUND	2,850,870	0	For
Capital Group	2,639,604	0	For
Lord Abbett	2,610,623	0	For
Invesco	2,333,085	0	For
VanEck ETF Trust	2,238,380	0	For
Janney Montgomery Scott LLC	2,128,690	0	For
TIAA	1,994,279	0	For
SOUND SHORE FUND INC	1,812,880	0	For
State Street	1,723,214	0	For
Dimensional	1,217,664	0	For
John Hancock	1,024,840	0	For
STERLING CAPITAL FUNDS	928,488	0	For
Aberdeen	819,873	0	For
DWS	736,067	0	For
HENNESSY FUNDS TRUST	652,100	0	For
CARILLON SERIES TRUST	491,922	0	For

Showing the 25 largest of 96 asset managers. See all 96 in the interactive database.

3. To approve the compensation to be provided to Teva's non- employee directors

COMPENSATIONMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 773,824,912AGAINST: 27,111,172

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“(5A) The shareholders approved an amendment to the compensation to be provided to Teva's non-employee Directors, as follows:”): 773,824,912 for, 27,111,172 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 67% for, 2% against (70% of the company cast a for/against vote).

The 95 asset managers below cast 96% of the shares they voted on this item FOR (184,313,640 for, 7,457,294 against).

FOR 96%

FOR: 184,313,640 (96.1%)AGAINST: 7,457,294 (3.9%)ABSTAIN: 32,666 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “To approve the compensation to be provided to Teva's non- employee directors” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
Fidelity	61,691,893	0	For
Vanguard	28,917,292	0	For
BlackRock	22,325,535	0	For
Lingotto Investment Management LLP	18,297,095	0	For
SOUND SHORE MANAGEMENT INC /CT/	9,041,532	0	For
Y.D. More Investments Ltd	0	7,096,532	Against
Allspring	4,566,476	0	For
Charles Schwab	3,535,795	0	For
Victory Capital	3,259,354	0	For
JANUS INVESTMENT FUND	2,850,870	0	For
Capital Group	2,639,604	0	For
Lord Abbett	2,610,623	0	For
Invesco	2,333,085	0	For
VanEck ETF Trust	2,238,380	0	For
Janney Montgomery Scott LLC	2,128,690	0	For
TIAA	1,994,279	0	For
SOUND SHORE FUND INC	1,812,880	0	For
State Street	1,723,214	0	For
Dimensional	1,217,664	0	For
John Hancock	1,024,840	0	For
STERLING CAPITAL FUNDS	928,488	0	For
Aberdeen	819,873	0	For
DWS	736,067	0	For
HENNESSY FUNDS TRUST	652,100	0	For
CARILLON SERIES TRUST	491,922	0	For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

4. To approve an amended compensation policy with respect to the terms of office and employment of Teva's Executive Officers and Directors

COMPENSATION

Combines 5 wordings of this item as funds reported it.

97% fund support · no official result

FOR 97%

The 92 asset managers below cast 97% of the shares they voted on this item FOR (208,436,533 for, 7,492,172 against).

FOR: 208,436,533 (96.5%)AGAINST: 7,492,172 (3.5%)ABSTAIN: 32,666 (0.0%)A: 900 (0.0%)

Largest asset managers voting on “To approve an amended compensation policy with respect to the terms of office and employment of Teva's Executi” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
Fidelity	61,691,893	0	For
BlackRock	57,874,804	0	For
Vanguard	28,917,292	0	For
Lingotto Investment Management LLP	18,297,095	0	For
Y.D. More Investments Ltd	0	7,096,532	Against
Allspring	4,566,476	0	For
Charles Schwab	3,535,795	0	For
Victory Capital	3,259,354	0	For
JANUS INVESTMENT FUND	2,850,870	0	For
Capital Group	2,639,604	0	For
Lord Abbett	2,610,623	0	For
Invesco	2,333,085	0	For
VanEck ETF Trust	2,238,380	0	For
Janney Montgomery Scott LLC	2,128,690	0	For
TIAA	1,994,279	0	For
State Street	1,723,214	0	For
Dimensional	1,217,664	0	For
John Hancock	957,400	0	For
STERLING CAPITAL FUNDS	928,488	0	For
Aberdeen	819,873	0	For
DWS	736,067	0	For
HENNESSY FUNDS TRUST	652,100	0	For
CARILLON SERIES TRUST	491,922	0	For
Pacific Life	461,792	0	For
Nationwide	448,418	0	For

Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.

5. To approve an amendment to the terms of office and employment of Teva's President and Chief Executive Officer

COMPENSATION

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 83 asset managers below cast 99.9% of the shares they voted on this item FOR (156,381,592 for, 34,800 against).

FOR: 156,381,592 (100.0%)AGAINST: 34,800 (0.0%)ABSTAIN: 32,666 (0.0%)A: 900 (0.0%)

Largest asset managers voting on “To approve an amendment to the terms of office and employment of Teva's President and Chief Executive Officer” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Vote
Fidelity	61,691,893	For
Vanguard	28,917,292	For
BlackRock	22,325,535	For
Allspring	4,566,476	For
Charles Schwab	3,535,795	For
Victory Capital	3,259,354	For
JANUS INVESTMENT FUND	2,850,870	For
Capital Group	2,639,604	For
Lord Abbett	2,610,623	For
Invesco	2,333,085	For
VanEck ETF Trust	2,238,380	For
Janney Montgomery Scott LLC	2,128,690	For
TIAA	1,994,279	For
SOUND SHORE FUND INC	1,812,880	For
State Street	1,723,214	For
Dimensional	1,217,664	For
John Hancock	957,400	For
STERLING CAPITAL FUNDS	928,488	For
Aberdeen	819,873	For
DWS	736,067	For
HENNESSY FUNDS TRUST	652,100	For
CARILLON SERIES TRUST	491,922	For
Pacific Life	461,792	For
Nationwide	448,418	For
Gabelli	440,075	For

Showing the 25 largest of 83 asset managers. See all 83 in the interactive database.

6. TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL TEVA'S 2026 ANNUAL MEETING OF SHAREHOLDERS

AUDIT-RELATEDMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 820,210,234AGAINST: 35,027,740

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“(6) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd.”): 820,210,234 for, 35,027,740 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 72% for, 3% against (75% of the company cast a for/against vote).

The 82 asset managers below cast 99.9% of the shares they voted on this item FOR (154,151,684 for, 136,205 against).

FOR 99.8%

FOR: 154,151,684 (99.9%)AGAINST: 136,205 (0.1%)ABSTAIN: 32,666 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Vote
Fidelity	61,691,893	For
Vanguard	28,917,292	For
BlackRock	22,325,535	For
Allspring	4,566,476	For
Charles Schwab	3,535,795	For
Victory Capital	3,259,354	For
JANUS INVESTMENT FUND	2,850,870	For
Capital Group	2,639,604	For
Lord Abbett	2,610,623	For
Invesco	2,333,085	For
VanEck ETF Trust	2,238,380	For
TIAA	1,994,279	For
SOUND SHORE FUND INC	1,812,880	For
State Street	1,723,214	For
Dimensional	1,217,664	For
John Hancock	957,400	For
STERLING CAPITAL FUNDS	928,488	For
Aberdeen	819,873	For
DWS	736,067	For
HENNESSY FUNDS TRUST	652,100	For
CARILLON SERIES TRUST	491,922	For
Pacific Life	461,792	For
Nationwide	448,418	For
Gabelli	440,075	For
Equitable	425,163	For

Showing the 25 largest of 82 asset managers. See all 82 in the interactive database.

7. ELECTION OF DIRECTORS: Chen Lichtenstein - to serve until Teva's 2027 Annual Meeting

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%

FOR: 654,450,171AGAINST: 135,306,461

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Chen Lichtenstein”): 654,450,171 for, 135,306,461 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 57% for, 12% against (69% of the company cast a for/against vote).

The 81 asset managers below cast 100% of the shares they voted on this item FOR (153,001,495 for, 0 against).

FOR 99.9%

FOR: 153,001,495 (100.0%)ABSTAIN: 32,666 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Chen Lichtenstein - to serve until Teva's 2027 Annual Meeting” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Vote
Fidelity	61,691,893	For
Vanguard	28,917,292	For
BlackRock	22,325,535	For
Allspring	4,566,476	For
Charles Schwab	3,535,795	For
Victory Capital	3,259,354	For
JANUS INVESTMENT FUND	2,850,870	For
Capital Group	2,639,604	For
Lord Abbett	2,610,623	For
Invesco	2,333,085	For
VanEck ETF Trust	2,238,380	For
TIAA	1,994,279	For
State Street	1,723,214	For
Dimensional	1,217,664	For
John Hancock	1,024,840	For
STERLING CAPITAL FUNDS	928,488	For
Aberdeen	819,873	For
DWS	736,067	For
HENNESSY FUNDS TRUST	652,100	For
CARILLON SERIES TRUST	491,922	For
Pacific Life	461,792	For
Nationwide	448,418	For
Gabelli	440,075	For
Equitable	425,163	For
Empower	405,012	For

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

8. ELECTION OF DIRECTORS: Amir Elstein - to serve until Teva's 2028 Annual Meeting

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%AGAINST 22%

FOR: 628,249,902AGAINST: 172,959,185

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Amir Elstein”): 628,249,902 for, 172,959,185 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 54.8% for, 15% against (70% of the company cast a for/against vote).

The 81 asset managers below cast 98% of the shares they voted on this item FOR (150,558,392 for, 2,443,103 against).

FOR 98%

FOR: 150,558,392 (98.4%)AGAINST: 2,443,103 (1.6%)ABSTAIN: 32,666 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Amir Elstein - to serve until Teva's 2028 Annual Meeting” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
Fidelity	61,691,893	0	For
Vanguard	28,917,292	0	For
BlackRock	22,325,535	0	For
Allspring	4,566,476	0	For
Charles Schwab	3,535,795	0	For
Victory Capital	3,259,354	0	For
JANUS INVESTMENT FUND	2,850,870	0	For
Capital Group	2,639,604	0	For
Lord Abbett	2,610,623	0	For
Invesco	0	2,333,085	Against
VanEck ETF Trust	2,238,380	0	For
TIAA	1,994,279	0	For
State Street	1,723,214	0	For
Dimensional	1,217,664	0	For
John Hancock	1,024,840	0	For
STERLING CAPITAL FUNDS	928,488	0	For
Aberdeen	819,873	0	For
DWS	736,067	0	For
HENNESSY FUNDS TRUST	652,100	0	For
CARILLON SERIES TRUST	491,922	0	For
Pacific Life	461,792	0	For
Nationwide	448,418	0	For
Gabelli	440,075	0	For
Equitable	364,285	60,878	For
Empower	405,012	0	For

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

9. ELECTION OF DIRECTORS: Dr. Tal Zaks to serve until Teva's 2028 Annual Meeting

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%

FOR: 653,460,760AGAINST: 136,254,343

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Dr. Tal Zaks”): 653,460,760 for, 136,254,343 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 57% for, 12% against (69% of the company cast a for/against vote).

The 81 asset managers below cast 99.9% of the shares they voted on this item FOR (152,914,399 for, 87,096 against).

FOR 99.9%

FOR: 152,914,399 (99.9%)AGAINST: 87,096 (0.1%)ABSTAIN: 32,666 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Dr. Tal Zaks to serve until Teva's 2028 Annual Meeting” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
Fidelity	61,691,893	0	For
Vanguard	28,917,292	0	For
BlackRock	22,325,535	0	For
Allspring	4,566,476	0	For
Charles Schwab	3,535,795	0	For
Victory Capital	3,259,354	0	For
JANUS INVESTMENT FUND	2,850,870	0	For
Capital Group	2,639,604	0	For
Lord Abbett	2,610,623	0	For
Invesco	2,333,085	0	For
VanEck ETF Trust	2,238,380	0	For
TIAA	1,994,279	0	For
State Street	1,723,214	0	For
Dimensional	1,217,664	0	For
John Hancock	1,024,840	0	For
STERLING CAPITAL FUNDS	928,488	0	For
Aberdeen	819,873	0	For
DWS	736,067	0	For
HENNESSY FUNDS TRUST	652,100	0	For
CARILLON SERIES TRUST	491,922	0	For
Pacific Life	461,792	0	For
Nationwide	448,418	0	For
Gabelli	440,075	0	For
Equitable	364,285	60,878	For
Empower	405,012	0	For

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

10. ELECTION OF DIRECTORS: Dr. Perry D. Nisen to serve until Teva's 2028 Annual Meeting

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 644,697,802AGAINST: 145,078,739

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Dr. Perry D. Nisen”): 644,697,802 for, 145,078,739 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 56% for, 13% against (69% of the company cast a for/against vote).

The 81 asset managers below cast 99.9% of the shares they voted on this item FOR (152,914,399 for, 87,096 against).

FOR 99.9%

FOR: 152,914,399 (99.9%)AGAINST: 87,096 (0.1%)ABSTAIN: 32,666 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Dr. Perry D. Nisen to serve until Teva's 2028 Annual Meeting” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
Fidelity	61,691,893	0	For
Vanguard	28,917,292	0	For
BlackRock	22,325,535	0	For
Allspring	4,566,476	0	For
Charles Schwab	3,535,795	0	For
Victory Capital	3,259,354	0	For
JANUS INVESTMENT FUND	2,850,870	0	For
Capital Group	2,639,604	0	For
Lord Abbett	2,610,623	0	For
Invesco	2,333,085	0	For
VanEck ETF Trust	2,238,380	0	For
TIAA	1,994,279	0	For
State Street	1,723,214	0	For
Dimensional	1,217,664	0	For
John Hancock	1,024,840	0	For
STERLING CAPITAL FUNDS	928,488	0	For
Aberdeen	819,873	0	For
DWS	736,067	0	For
HENNESSY FUNDS TRUST	652,100	0	For
CARILLON SERIES TRUST	491,922	0	For
Pacific Life	461,792	0	For
Nationwide	448,418	0	For
Gabelli	440,075	0	For
Equitable	364,285	60,878	For
Empower	405,012	0	For

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

11. ELECTION OF DIRECTORS: Roberto A. Mignone to serve until Teva's 2028 Annual Meeting]

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST 17%

FOR: 652,577,603AGAINST: 137,177,350

TEVA PHARMACEUTICAL INDUSTRIES LTD.’s own tally for this item (“Elect Director: Roberto A. Mignone”): 652,577,603 for, 137,177,350 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,146,959,855 outstanding shares: 57% for, 12% against (69% of the company cast a for/against vote).

The 81 asset managers below cast 99.9% of the shares they voted on this item FOR (152,903,511 for, 97,984 against).

FOR 99.9%

FOR: 152,903,511 (99.9%)AGAINST: 97,984 (0.1%)ABSTAIN: 32,666 (0.0%)UNKNOWN: 900 (0.0%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Roberto A. Mignone to serve until Teva's 2028 Annual Meeting]” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
Fidelity	61,691,893	0	For
Vanguard	28,917,292	0	For
BlackRock	22,325,535	0	For
Allspring	4,566,476	0	For
Charles Schwab	3,535,795	0	For
Victory Capital	3,259,354	0	For
JANUS INVESTMENT FUND	2,850,870	0	For
Capital Group	2,639,604	0	For
Lord Abbett	2,610,623	0	For
Invesco	2,333,085	0	For
VanEck ETF Trust	2,238,380	0	For
TIAA	1,994,279	0	For
State Street	1,723,214	0	For
Dimensional	1,217,664	0	For
John Hancock	1,024,840	0	For
STERLING CAPITAL FUNDS	928,488	0	For
Aberdeen	819,873	0	For
DWS	736,067	0	For
HENNESSY FUNDS TRUST	652,100	0	For
CARILLON SERIES TRUST	491,922	0	For
Pacific Life	461,792	0	For
Nationwide	448,418	0	For
Gabelli	440,075	0	For
Equitable	364,285	60,878	For
Empower	405,012	0	For

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

12. APPROVE COMPENSATION POLICY FOR THE DIRECTORS AND OFFICERS OF THE COMPANY

COMPENSATIONCORPORATE GOVERNANCE

93% fund support · no official result

FOR 93%7%

The 6 asset managers below cast 93% of the shares they voted on this item FOR (1,171,917 for, 89,365 against).

FOR: 1,171,917 (92.9%)AGAINST: 89,365 (7.1%)

Largest asset managers voting on “APPROVE COMPENSATION POLICY FOR THE DIRECTORS AND OFFICERS OF THE COMPANY” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Vote
BlackRock	734,796	0	For
Empower	202,912	0	For
Jackson National	164,121	0	For
HC CAPITAL TRUST	0	89,365	Against
John Hancock	67,440	0	For
Allianz	2,648	0	For

13. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 5 asset managers below cast 100% of the shares they voted on this item FOR (3,295,179 for, 0 against).

FOR: 3,295,179 (100.0%)

Largest asset managers voting on “14A Executive Compensation” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Vote
DME Capital Management, LP	3,289,473	For
Focus Partners Wealth	3,931	For
MQS Management LLC	1,265	For
EAGLE GLOBAL ADVISORS LLC	500	For
Claret Asset Management Corp	10	For

14. AMEND ARTICLES RE: TERMS AND EMPLOYMENT OF PRESIDENT AND CEO

OTHER

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (234,209 for, 0 against).

FOR: 234,209 (100.0%)

Largest asset managers voting on “AMEND ARTICLES RE: TERMS AND EMPLOYMENT OF PRESIDENT AND CEO” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Vote
Jackson National	164,121	For
John Hancock	67,440	For
Allianz	2,648	For

15. RATIFY KESSELMAN AND KESSELMAN AS AUDITORS

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (234,209 for, 0 against).

FOR: 234,209 (100.0%)

Largest asset managers voting on “RATIFY KESSELMAN AND KESSELMAN AS AUDITORS” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Vote
Jackson National	164,121	For
John Hancock	67,440	For
Allianz	2,648	For

16. Proposal 4: To approve an amendment to the terms of office and employment of Teva's President and CEO.

SECTION 14A SAY-ON-PAY VOTES

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 7,457,294 against).

AGAINST: 7,457,294 (100.0%)

Largest asset managers voting on “Proposal 4: To approve an amendment to the terms of office and employment of Teva's President and CEO.” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Y.D. More Investments Ltd	0	7,096,532	0	0	Against
Altshuler Shaham Ltd	0	360,762	0	0	Against

17. Amend Employment Terms of the CEO of the Company

COMPENSATION

69% fund support · no official result

FOR 69%AGAINST 31%

The 2 asset managers below cast 69% of the shares they voted on this item FOR (202,912 for, 89,365 against).

FOR: 202,912 (69.4%)AGAINST: 89,365 (30.6%)

Largest asset managers voting on “Amend Employment Terms of the CEO of the Company” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Empower	202,912	0	0	0	For
HC CAPITAL TRUST	0	89,365	0	0	Against

18. Approve Remuneration Policy

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (2,198,665 for, 0 against).

FOR: 2,198,665 (100.0%)

Largest asset managers voting on “Approve Remuneration Policy” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Eversept Partners, LP	2,182,158	0	0	0	For
Regime de rentes du Mouvement Desjardins	16,507	0	0	0	For

19. Ratify Kesselman & Kesselman as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (292,277 for, 0 against).

FOR: 292,277 (100.0%)

Largest asset managers voting on “Ratify Kesselman & Kesselman as Auditors” at TEVA PHARMACEUTICAL INDUSTRIES LTD., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Empower	202,912	0	0	0	For
HC CAPITAL TRUST	89,365	0	0	0	For

Largest TEVA PHARMACEUTICAL INDUSTRIES LTD. shareholders voting in 2024-2025

Ranked by the number of TEVA PHARMACEUTICAL INDUSTRIES LTD. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 1,146,959,855 shares outstanding at the time of that meeting.

Top TEVA PHARMACEUTICAL INDUSTRIES LTD. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	12.53%
2	BlackRock	5.11%
3	Vanguard	3.68%
4	Clal Insurance Enterprises Holdings Ltd	3.24%
5	MENORA MIVTACHIM HOLDINGS LTD.	2.57%
6	Phoenix Financial Ltd.	2.44%
7	Rubric Capital Management LP	1.71%
8	Lingotto Investment Management LLP	1.60%
9	State Street	1.51%
10	Duquesne Family Office LLC	1.39%

Reported TEVA PHARMACEUTICAL INDUSTRIES LTD. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

TEVA PHARMACEUTICAL INDUSTRIES LTD. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	7.21%	13F
Harel Insurance Investments & Financial Services Ltd	6.31%	13G
Migdal Insurance & Financial Holdings Ltd	5.38%	13G
Menora Mivtachim Holdings Ltd	5.00%	13G
Phoenix Financial Ltd.	5.00%	13G
BlackRock	4.55%	13F
State Street	1.51%	13F
Morgan Stanley	0.96%	13F
Goldman Sachs	0.90%	13F
Geode Capital	0.80%	13F

Percentages above are of 1,146,959,855 shares outstanding, as reported by TEVA PHARMACEUTICAL INDUSTRIES LTD. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from TEVA PHARMACEUTICAL INDUSTRIES LTD.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At TEVA PHARMACEUTICAL INDUSTRIES LTD.'s shareholder meeting held 2025-06-05, in the 2024-2025 proxy season, 530 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,762 separate fund positions. Their filings are grouped here into 19 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation for Teva's named executive… — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: TEVA PHARMACEUTICAL INDUSTRIES LTD.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-05.

TEVA PHARMACEUTICAL INDUSTRIES LTD. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.